Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00463541
Status:
COMPLETED
Last Update Posted:
2014-09-18
First Post:
2007-04-19
Brief Title:
Open-label Study of the Efficacy and Safety of VESIcare in Patients With Overactive Bladder Symptoms
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
An Open-label Study of the Efficacy and Safety of 5 and 10mg VESIcare Solifenacin Succinate in Patients With Overactive Bladder Symptoms VOLT VESIcare Open-Label Trial
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VOLT
Brief Summary:
To evaluate the safety and efficacy of solifenacin succinate in subjects with overactive bladder symptoms urgency with or without urge incontinence usually with frequency and nocturia
Detailed Description:
Study included a 24 week extension that did not occur due to FDA approval of the product
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None